Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with...

Abstract

The BCR-ABL tyrosine kinase inhibitor STI571 is well tolerated and has substantial activity in the blast crises of CML and in Ph-positive ALL.

Keywords

MedicinePhiladelphia chromosomeMyeloid leukemiaTyrosine-kinase inhibitorInternal medicineMyeloidTyrosine kinaseLeukemiaImmunologyCancer researchChromosomal translocationCancerBiology

Affiliated Institutions

Related Publications

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

Elias Jabbour , Hagop M. Kantarjian

Disease overview : Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1–2 cases per 100,000 adults, and accounts for ∼15% of newly diagnosed ca...

2014 American Journal of Hematology 210 citations

Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.

Ernest S. Kawasaki , SS Clark , Mazie Coyne +4 more

The Philadelphia chromosome is present in more than 95% of chronic myeloid leukemia patients and 13% of acute lymphocytic leukemia patients. The Philadelphia translocation, t(9;...

1988 Proceedings of the National Academy o... 721 citations

Diagnosing and Managing Advanced Chronic Myeloid Leukemia

Michael W. Deininger

Clinical staging of chronic myeloid leukemia (CML) distinguishes between chronic phase (CP-CML), accelerated phase (AP-CML), and blastic phase (BP-CML), reflecting its natural h...

2015 American Society of Clinical Oncology... 28 citations

Chronic Myelogenous Leukemia, Version 1.2015

Susan O’Brien , Jerald P. Radich , Camille N. Abboud +20 more

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase)...

2014 Journal of the National Comprehensive... 71 citations

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Michele Baccarani , Michael Deininger , Gianantonio Rosti +29 more

Abstract Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European Leuke...

2013 Blood 1953 citations

Publication Info

Year: 2001
Type: article
Volume: 344
Issue: 14
Pages: 1038-1042
Citations: 2710
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2710

OpenAlex

Cite This

APA Style

                            
                                
                                    Brian Druker, 
                                
                                    Charles L. Sawyers, 
                                
                                    Hagop M. Kantarjian
                                
                                et al.
                            
                            (2001). 
                            Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome. 
                            New England Journal of Medicine
                            , 344
                            (14)
                            , 1038-1042.
                            https://doi.org/10.1056/nejm200104053441402
                        

Identifiers

DOI: 10.1056/nejm200104053441402